

The invention relates to an isolated PRO52254 nucleic acid. Further disclosed is a vector comprising the nucleic acid. The PRO52254 nucleic acid or polypeptide is useful for preparing a composition for diagnosing or treating an immune related disorder, e.g., systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, spondyloarthritis, systemic sclerosis, juvenile chronic inflammatory myopathy, Sjogren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, a idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome, a inflammatory demyelinating polyneuropathy, hepatobiliary disease, chronic infectious or autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, sclerosing cholangitis, inflammatory bowel disease, gluten-sensitive enteropathy, Whipple's disease, autoimmune or immune-mediated skin disease, bullous skin disease, erythema multiforme, contact dermatitis, psoriasis, allergic disease, asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity, urticaria, immunologic disease of the lung, eosinophilic pneumonia, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, transplantation associated disease, graft rejection or graft-versus-host disease. The current sequence represents the PRO52245 nucleotide sequence.

Sequence 831 BP; 186 A; 234 C; 238 G; 173 T; 0 U; 0 Other;

Query Match 100.0%; Score 831; DB 12; Length 831; Best Local Similarity 100.0%; Pred. No. 4, 6e-226; Matches 831; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

1  CGTCTATGCGAGGCGGCTTCTTCTGCGAGGAGGCGGCACTGCTCTCTAGG 60
1  CGTCTATGCGAGGCGGCTTCTTCTGCGAGGAGGCGGCACTGCTCTCTAGG 60
61  CCTCTGCGGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 120
61  CCTCTGCGGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 120
61  CCTCTGCGGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 120
121  GGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 180
121  GGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 180
181  AGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 240
181  AGAGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 240
241  CGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 300
241  CGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 300
301  GCACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 360
301  GCACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 360
361  CGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 420
361  CGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 420
421  TGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 480
421  TGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 480
481  TGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 540
481  TGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 540
541  AGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 600
541  AGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 600
601  GGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 660
601  GGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 660

```

```

Db 601 GGAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 660
Qy 661 ACCCCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 720
Db 661 ACCCCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 720
Qy 721 GGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 780
Db 721 GGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 780
Qy 781 TAACTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 831
Db 781 TAACTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 831

```

RESULT 2

ID ADA21190 standard; cDNA; 1711 BP.

AC ADA21190;

DT 20-NOV-2003 (first entry)

DE Human secreted protein SECP-44 encoding cDNA SEQ ID NO:95.

KW human; secreted protein; SECP; anti-HIV; antiallergic; antiinflammatory;
KW antianemic; antiparkinsonian; nootropic; anticonvulsant;
KW antileukemic; antileukemia; antileukemic; immunosuppressive; antithyroid;
KW cytosolic; hepatocytic; dermatological; antidiabetic; nephrotropic;
KW antitumor; thymic; neuroprotective; osteopathic; antileukemic;
KW antiparasitic; antihelminthic; antiparasitic; uterine;
KW protozoic; fungicide; gene therapy; cell proliferative; disorder;
KW arteriosclerosis; atherosclerosis; cirrhosis; hepatitis;
KW paroxysmal nocturnal haemoglobinuria; polycythemia vera; psoriasis;
KW primary thrombocytopenia; cancer; developmental disorder;
KW renal tubular acidosis; anemia; mental retardation;
KW neurological disorder; Alzheimer's disease; Parkinson's disease;
KW epilepsy; autoimmune disorder; inflammatory disorder; AIDS; allergy;
KW asthma; autoimmune thyroiditis; contact dermatitis; Crohn's disease;
KW diabetes mellitus; glomerulonephritis; Goodpasture's syndrome; gout;
KW Graves' disease; Hashimoto's thyroiditis; irritable bowel syndrome;
KW multiple sclerosis; osteoarthritis; osteoporosis; pancreatitis;
KW Reiter's syndrome; rheumatoid arthritis; Sjogren's syndrome; uveitis;
KW infection; gene; ss.

OS Homo sapiens.

PN MO2003068943-A2.

PD 21-AUG-2003.

PE 13-FEB-2003; 2003MO-US004712.

PR 13-FEB-2002; 2002US-0357002P.

PR 06-MAR-2002; 2002US-0362439P.

PR 19-MAR-2002; 2002US-036041P.

PA (INCY-) INCYTE GENOMICS INC.

PI Lehr-Mason PM, Kable AE, Elliott VS, Margolis JP, Baughn MR;
PI Chawla NK, Tien UK, Jin P, Tang YT, Zebajadlan Y, Swarnakar A;
PI Hafalia ALA, Cocks BG, Warren BA, Emerling BM, Pearson CJ, Chien D;
PI Peterson DP, Fu GK, Yue H, Jackson AA, Jiang X, Hawkins PR, Lal PG;
PI Khare R, Lee S, Lee SY, Richardson TW, Chang H;

DR MPI; 2003-689669/65.

DR P-PSDB; ADA21139.

PT New human secreted proteins and polynucleotides, useful for diagnosing,
PT treating or preventing autoimmune or inflammatory disorders (e.g. AIDS,
PT allergy, asthma or anemia), multiple sclerosis, osteoporosis, cancer or
PT hepatitis.

CC vasotropic, cerebroprotective; nootropic; neuroprotective; antibacterial,
CC vincidine; fungicide; ophthalmologic, and urological. The secreted
CC proteins, polypeptides, antagonists and agonists may be useful in
CC treating, preventing and/or diagnosing diseases and disorders such as
CC autoimmune diseases e.g. Rheumatoid arthritis, hyperproliferative
CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC angiodysplasia, nervous system disorders e.g. Alzheimer's disease,
CC infections caused by bacteria, viruses and fungi and ocular disorders
CC e.g. corneal infection. The polypeptides can also be used to aid wound
CC healing and epithelial cell proliferation, to prevent skin aging due to
CC sunburn, to maintain organs before transplantation, for supporting cell
CC culture of primary tissues, to regenerate tissues and in chemotaxis. The
CC polypeptides can also be used as a food additive or preservative to
CC increase or decrease storage capabilities, fat content, lipid, protein,
CC carbohydrate, vitamins, minerals, cofactors and other nutritional
CC components. Oligonucleotides AAC95453 - AAC95461 and peptide AB51928 are
CC used in the isolation and characterisation of the proteins and
CC polynucleotides of the invention

Sequence 1332 BP; 326 A; 319 C; 329 G; 358 T; 0 U; 0 Other;

Query Match	98.5%; Score 818.4; DB 3; Length 1332;
Best Local Similarity	98.8%; Prod No 3 30-333;

Matches 830; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

Matches 830; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY	1	CGTCCATCTGCAAGTCGGCTACTTTCAGT-GGCAAGAAAGGCAACATGCTCTCTGAG	59
Db	235	CGTCCATCTGCAAGTCGGCTACTTTCAGTGGGCAAGAGGCCACATGCTCTCTCTGAG	29
QY	60	GCCCTCTGGGGCAAGAACATGCGCTGGTGTCTCTCTCTGATCTGGGGCCAGGGGCTGAGGC	119
Db	295	GCCCTCTGGGGCAAGAACATGCGCTGGTGTCTCTCTCTGATCTGGGGCCAGGGGCTGAGGC	35
QY	120	AGGCTCCCTCGCCTCAGGATATGATGACAGGACCAATATGAAACAAGGGGAACATTTCTG	179
Db	355	AGGCTCCCTCGCCTCAGGATATGATGACAGGACCAATATGAAACAAGGGGAACATTTCTG	414
QY	180	CAGAGAAAGTGGCTCTATCATCTTTCATATCTTTCACCTCTCTCCACACAGGCAACATGTA	239
Db	415	CAGAGAAAGTGGCTCTATCATCTTTCATATCTTTCACCTCTCTCCACACAGGCAACATGTA	474
QY	240	CCAGGATCAACTGGGAGCAGAGAACAGGCTTCTGGGCAATTGTAATGCTGACTTGGGGGT	299
Db	475	CCAGGATCAACTGGGAGCAGAGAACAGGCTTCTGGGCAATTGTAATGCTGACTTGGGGGT	534
QY	300	GGCACATCTCCCATCTTCAAGATTCAGTGGCCCGCAGGTCCCGGCTGGGCTCTCAACC	359
Db	535	GGCACATCTCCCATCTTCAAGATTCAGTGGCCCGCAGGTCCCGGCTGGGCTCTCAACC	594
QY	360	TTCAGTCTGGTGAACGTTGAACCATTAACGGGAGATCTTGTGATCTTATCAACCTACCTG	419
Db	595	TTCAGTCTGGTGAACGTTGAACCATTAACGGGAGATCTTGTGATCTTATCAACCTACCTG	654
QY	420	ATGGGACGTACACTGGGAGAACTCTCTCGAGAGTCTTAGAAAGCTCAGTGGCTGAGACG	479
Db	655	ATGGGACGTACACTGGGAGAACTCTCTCGAGAGTCTTAGAAAGCTCAGTGGCTGAGACG	714
QY	480	GTCGCAAGTTCCAAATTCATTTGCTTGGAGCCATGGCCGACGCTGTGTCTCATCTGCA	539
Db	715	GTCGCAAGTTCCAAATTCATTTGCTTGGAGCCATGGCCGACGCTGTGTCTCATCTGCA	774
QY	540	CAGCAGTCACTGTGTGTGTGTCGTTGACTTAAAGAGAAAGAAAGCCCTCAAGATTCATCTG	599
Db	775	CAGCAGTCACTGTGTGTGTGTCGTTGACTTAAAGAGAAAGAAAGCCCTCAAGATTCATCTG	834
QY	600	TGAGAAAGTGAACCTCAGAGAAAAATCAGCTGACAGAGGAATGAGGCCCAAGTCTCCCT	659
Db	835	TGAGAAAGTGAACCTCAGAGAAAAATCAGCTGACAGAGGAATGAGGCCCAAGTCTCCCT	894
QY	660	CACCCCAAGAAAGCTGTGTCCAGAGCAAGAGCTGCACTGTGGCTCTGTGTGAGACAGC	719
Db	895	CACCCCAAGAAAGCTGTGTGTCCAGAGCAAGAGCTGCACTGTGGCTCTGTGTGAGACAGC	954

Accession	Sequence	Length
Qy	GGGAGAGGAACTGGCCAGCTGATACAACTTCATGCTCAGTTACAGAGCCCTG	779
Db	GGGAGAGGAACTGGCCAGCTGATACAACTTCATGCTCAGTTACAGAGCCCTG	1014
Qy	GTAACCTCAGCTCTTCAAGAGCTGTGACAAACAGAGGAACTCTCTG	831
Db	GTAACCTCAGCTCTTCAAGAGCTGTGACAAACAGAGGAACTCTCTCTG	1066

RESULT

ADL91491

ID	ADL91491	standard; cDNA; 1332 BP.
1	1	1
2	2	2
3	3	3
4	4	4
5	5	5
6	6	6
7	7	7
8	8	8
9	9	9
10	10	10
11	11	11
12	12	12
13	13	13
14	14	14
15	15	15
16	16	16
17	17	17
18	18	18
19	19	19
20	20	20
21	21	21
22	22	22
23	23	23
24	24	24
25	25	25
26	26	26
27	27	27
28	28	28
29	29	29
30	30	30
31	31	31
32	32	32
33	33	33
34	34	34
35	35	35
36	36	36
37	37	37
38	38	38
39	39	39
40	40	40
41	41	41
42	42	42
43	43	43
44	44	44
45	45	45
46	46	46
47	47	47
48	48	48
49	49	49
50	50	50
51	51	51
52	52	52
53	53	53
54	54	54
55	55	55
56	56	56
57	57	57
58	58	58
59	59	59
60	60	60
61	61	61
62	62	62
63	63	63
64	64	64
65	65	65
66	66	66
67	67	67
68	68	68
69	69	69
70	70	70
71	71	71
72	72	72
73	73	73
74	74	74
75	75	75
76	76	76
77	77	77
78	78	78
79	79	79
80	80	80
81	81	81
82	82	82
83	83	83
84	84	84
85	85	85
86	86	86
87	87	87
88	88	88
89	89	89
90	90	90
91	91	91
92	92	92
93	93	93
94	94	94
95	95	95
96	96	96
97	97	97
98	98	98
99	99	99
100	100	100

AC ADL91491;

DT 17-JUN-2004 (first entry)

Human immune-related polypeptide PRO52254-encoding cDNA, SEQ ID NO:6.

Human; PRO; activated T cell; immune-related; drug screening; detection;
stimulation; immune response; stimulation; diagnosis; immune disorder;
systemic lupus erythematosus; rheumatoid arthritis; osteoarthritis;
juvenile chronic arthritis; spondyloarthropathy; systemic sclerosis;
idiopathic inflammatory myopathy; Sjogren's syndrome;
systemic vasculitis; sarcoidosis; autoimmune haemolytic anaemia;
autoimmune thrombocytopenia; thyroiditis; diabetes mellitus;
immune-mediated renal disease; demyelinating disease;
idiopathic demyelinating polyneuropathy; Guillain-Barre syndrome;
chronic inflammatory demyelinating polyneuropathy; hepatobiliary disease
chronic active hepatitis; primary biliary cirrhosis;
granulomatous hepatitis; sclerosing cholangitis;
inflammatory bowel disease; gluten-sensitive enteropathy;
Whipple's disease; autoimmune skin disease; immune-mediated
bullous skin disease; erythema multiforme; contact dermatitis; psoriasis
allergic disease; asthma; allergic rhinitis; atopic dermatitis;
food hypersensitivity; urticaria; eosinophilic pneumonia;
idiopathic pulmonary fibrosis; hypersensitivity pneumonitis;
transplantation associated disease; graft rejection;
graft-versus-host-disease; immunosuppressive; dermatological;
hepatotropic; nephrotropic; antidiabetic; antiasthmatic; antipsoriatic;
antiallergic; antianaemic; antiarteriosclerotic; antiarthritic;
neuroprotective; respiratory; antiinflammatory; gene therapy; gene; ss.

Homo sapiens.

WO2004024072-A2.
25-MAR-2004.
10-SEP-2003; 2003WO-US028317.
11-SEP-2002; 2002US-0410340P.
(GENTH) GENENTECH INC.
Bodary SC, Clark H, Hunte B, Jackman JK, Schoenfeld JR,
Williams PM, Wood WI, Wu TD;
WPI; 2004-329384/30.
P-PSDB; ADL91492.

New PRO nucleic acid, useful for preparing a composition for diagnosing
or treating an immune related disorder, e.g., systemic lupus
erythematosus in a mammal.

Claim 2; SEQ ID NO.6; 19pp; English.

The invention relates to isolated human immune-related polypeptides
(designated PRO) and nucleic acids (ADL91486-ADL91587). The PRO
polypeptides are overexpressed in CD4+ T cells activated by anti-CD3/TGM
-1 or anti-CD3/anti-CD28 antibodies compared with resting T cells and are
useful as diagnostic markers and therapeutic targets for immune

QY 61 QODQLAIACNADLGMHISPSFKDRAVAPGRLGLTQSLVNDNGFYCYHYHYPDGTYTG 120
DB 61 QODQLAIACNADLGMHISPSFKDRAVAPGRLGLTQSLVNDNGFYCYHYHYPDGTYTG 120
QY 121 RIFLEVLSSVAHEGARFQIPLGMAATLVITCAVTVVVALTRKKALRIHSVGDLR 180
DB 121 RIFLEVLSSVAHEGARFQIPLGMAATLVITCAVTVVVALTRKKALRIHSVGDLR 180
QY 181 RKSAGQEMSPSPSPSCVQAEAPAGLCEBQGBDCAELHDYFNVLSTYSLGNCSPF 240
DB 181 RKSAGQEMSPSPSPSCVQAEAPAGLCEBQGBDCAELHDYFNVLSTYSLGNCSPF 240
QY 241 TETG 244
DB 241 TETG 244

RESULT 3
ADP76825
ID ADF76825 standard; protein; 257 AA.
AC ADF76825;
DT 26-FEB-2004 (first entry)
DE Novel human secreted and transmembrane protein Seqid 500.
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour.
OS Homo sapiens.
XX WO2003072035-A2.
XX 04-SRP-2003.
XX 21-FEB-2003; 2003WO-US005241.
XX 22-FEB-2002; 2002US-0359461P.
XX (GETH) GENENTECH INC.
XX Bodary SC, Clark H, Hunte B, Jackman JK, Schoenfeld JR;
PI Williams FM, Wood WT, Wu TD;
XX WPI; 2003-721702/68.
XX N-PSDB; ADF76824.
PT New PRO polypeptides, useful for diagnosing and treating an immune
PT related disorder, e.g. systemic lupus erythematosus, rheumatoid
PT arthritis, osteoarthritis, juvenile chronic arthritis, thyroiditis or
PT diabetes mellitus.
XX Claim 10; SEQ ID NO 500; 918pp; English.
XX This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles
XX in the formation, differentiation and maintenance of multicellular
XX organisms. The fate of many individual cells (for example proliferation,
XX migration or differentiation) is typically governed by information
XX received from other cells and the immediate environment. The information
XX is often transmitted by secreted polypeptides (for example mitogenic
XX factors, survival factors, cytotoxic factors, differentiation factors,
XX neuropeptides and hormones) which are received and interpreted by diverse
XX cell receptors or membrane bound proteins. These membrane bound proteins
XX and receptors may be of use as pharmaceutical and diagnostic agents, such
XX as in the blocking of receptor-ligand interactions. The current invention
XX provides the amino acid sequences of novel human membrane bound receptors
XX and proteins, along with the cDNA sequences encoding them. The novel
XX proteins of the invention may have cytoskeletal activities through the

CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.
XX
SQ Sequence 257 AA;
Query Match 100.0%; Score 1286; DB 7; Length 257;
Best Local Similarity 100.0%; Pred. No. 1,2e-112;
Matches 244; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MENCILLIWAQGLRQAPLPSGMMTGTITRTGNIISARKGSIILQCHLSTTAQTVYVNE 60
DB 14 MENCILLIWAQGLRQAPLPSGMMTGTITRTGNIISARKGSIILQCHLSTTAQTVYVNE 73
QY 61 QODQLAIACNADLGMHISPSFKDRAVAPGRLGLTQSLVNDNGFYCYHYHYPDGTYTG 120
DB 74 QODQLAIACNADLGMHISPSFKDRAVAPGRLGLTQSLVNDNGFYCYHYHYPDGTYTG 133
QY 121 RIFLEVLSSVAHEGARFQIPLGMAATLVITCAVTVVVALTRKKALRIHSVGDLR 180
DB 134 RIFLEVLSSVAHEGARFQIPLGMAATLVITCAVTVVVALTRKKALRIHSVGDLR 193
QY 181 RKSAGQEMSPSPSPSCVQAEAPAGLCEBQGBDCAELHDYFNVLSTYSLGNCSPF 240
DB 194 RKSAGQEMSPSPSPSCVQAEAPAGLCEBQGBDCAELHDYFNVLSTYSLGNCSPF 253
QY 241 TETG 244
DB 254 TETG 257

RESULT 4
ADA21139
ID ADA21139 standard; protein; 311 AA.
XX ADA21139;
XX 20-NOV-2003 (first entry)
DE Human secreted protein SECP-44 SEQ ID NO:44.
KW human; secreted protein; SECP; anti-HIV; anti-allergic; anti-inflammatory;
KW antianemic; antiparkinsonian; noctropic; anticonvulsant;
KW antiarteriosclerotic; antiasthmatic; immunosuppressive; antithyroid;
KW cytoskeletal; hepatotropic; dermatological; antidiabetic; nephrotropic;
KW antigen; thymometric; neuroprotective; osteopathic; antiarthritic;
KW antiparasitic; antihelminthic; antipruritic; uropathic;
KW ophtalmological; antirheumatic; haemostatic; antibacterial; virucide;
KW protozoacide; fungicide; gene therapy; cell proliferative disorder;
KW arteriosclerosis; atherosclerosis; cirrhosis; hepatitis;
KW paroxysmal nocturnal haemoglobinuria; polycythaemia vera; porriasis;
KW primary thrombocytopaenia; cancer; developmental disorder;
KW renal tubular acidosis; anaemia; mental retardation;
KW neurological disorder; Alzheimer's disease; Parkinson's disease;
KW epilepsy; autoimmune disorder; inflammatory disorder; AIDS; allergy;
KW asthma; autoimmune thyroiditis; contact dermatitis; Crohn's disease;
KW diabetes mellitus; glomerulonephritis; Goodpasture's syndrome; gout;
KW Graves' disease; Hashimoto's thyroiditis; irritable bowel syndrome;
KW multiple sclerosis; osteoarthritis; osteoporosis; pancreatitis;
KW Ketter's syndrome; rheumatoid arthritis; Sjogren's syndrome; uveitis;
KW infection.
XX Homo sapiens.
XX WO2003068943-A2.
XX 21-AUG-2003.
XX 13-FEB-2003; 2003WO-US004712.

13-FEB-2002; 2002US-0357002P.
06-MAR-2002; 2002US-0362439P.
19-MAR-2002; 2002US-0366041P.

(INCY-) INCYTE GENOMICS INC.

Lehr-Mason PM, Kable AE, Elliott VS, Margulis JP, Baughn MR;
Chavala NK, Tran UK, Jin P, Tang YT, Zeharjadian Y, Sarnakar A;
Hafalia AD, Cocks BG, Warren BA, Emerling BM, Pearson CJ, Chien D;
Peterson DP, Pu GK, Yue H, Jackson AA, Jiang X, Hawkins PR, Lai PG;
Khare R, Lee S, Lee ST, Richardson TW, Chang H;

WPI; 2003-689669/65.
N-PSDB; ADA21190.

New human secreted proteins and polynucleotides, useful for diagnosing, treating or preventing autoimmune or inflammatory disorders (e.g. AIDS, allergy, asthma or anemia), multiple sclerosis, osteoporosis, cancer or hepatitis.

Claim 1; Page 245-246; 295pp; English.

The present sequence represents a human secreted protein (I) designated SECP-44. (I) have anti-HIV, anti-allergic, anti-inflammatory, anti-anemic, anti-parkinsonian, nootropic, anticonvulsant, antiarteriosclerotic, anti-asthmatic, immunosuppressive, antihypertensive, cytototoxic, hepatotropic, dematological, antidiabetic, nephrotropic, angiotensin, thyromimetic, neuroprotective, osteopathic, antirheumatic, antiparasitic, antihelminthic, antipsoriatic, uropathic, ophthalmological, antitubercular, hemostatic, antibacterial, virostatic, protozoacide and fungicide activities, and can be used in gene therapy. The human secreted proteins (SECP), polynucleotides, agonists and antagonists of the present invention are useful for diagnosing, treating or preventing disorders associated with aberrant expression of SECP, particularly cell proliferative disorders (e.g. arteriosclerosis, atherosclerosis, cirrhosis, hepatitis, paroxysmal nocturnal haemoglobinuria, polycythaemia vera, psoriasis, primary thrombocytopaenia or cancer), developmental disorders (e.g. renal tubular acidosis, anaemia or mental retardation), neurological disorders (e.g. Alzheimer's disease, Parkinson's disease or epilepsy), autoimmune/inflammatory disorders (e.g. AIDS, allergies, asthma, autoimmune thyroiditis, contact dermatitis, Crohn's disease, diabetes mellitus, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, irritable bowel syndrome, multiple sclerosis, osteoarthritis, osteoporosis, pancreatitis, Reiter's syndrome, rheumatoid arthritis, Sjogren's syndrome, uveitis), or viral, bacterial, fungal, parasitic, protozoan or helminthic infections. The SECP and polynucleotides are also useful in assessing the effects of exogenous compounds on the expression of nucleic acids secreted proteins. The polynucleotides encoding SECP are useful for creating transgenic animals to model human disease.

Sequence 311 AA;

Query Match 100.0%; Score 1286; DB 6; Length 311;
Best Local Similarity 100.0%; Pred. No. 1.6e-112;
Matches 244; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

1 MEMCILLIWAQGLRQAPLASGMGTGTTTETGNISAEKGSIILOCHSSTTAQVYVNB 60
68 MEMCILLIWAQGLRQAPLASGMGTGTTTETGNISAEKGSIILOCHSSTTAQVYVNB 127
61 OODOLLAICNADLGNIHSPSPFDVAPRGGLTLOSLTVNDTGEYFCIYHTYPPDQTYG 120
128 OODOLLAICNADLGNIHSPSPFDVAPRGGLTLOSLTVNDTGEYFCIYHTYPPDQTYG 187
121 RIFLEVLSSVAHGARGQIPILGMAATLVITCTAVIVVVALTRKKALRIHSVGDRL 180
188 RIFLEVLSSVAHGARGQIPILGMAATLVITCTAVIVVVALTRKKALRIHSVGDRL 247
181 RKSAGQEWSPSPSPSCVQABAPAGLCGROGDECAIHDYFNTLSYSLGNCSPF 240
248 RKSAGQEWSPSPSPSCVQABAPAGLCGROGDECAIHDYFNTLSYSLGNCSPF 307

```

241 TETG 244
308 TETG 311

RESULT 5
ADM05498
ID ADM05498 standard; protein; 244 AA.

ADM05498;

20-MAY-2004 (first entry)

Human protein of the invention SEQ ID NO:4183.

human; gene therapy; diagnostic marker; pharmaceutical.

Homo sapiens.

EP1347046-A1.

24-SEP-2003.

12-APR-2002; 2002EP-00008400.

22-MAR-2002; 2002JP-00137785.

(RMS-) RBS ASSOC BIOTECHNOLOGY.

Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;
Seki N, Yoshikawa T, Otsuka M, Nagahara K, Masuho Y;

WPI; 2003-723558/69.

N-PSDB; ADM03055.

New polynucleotides and polypeptides are useful in gene therapy, for developing a diagnostic marker or medicines for regulating their expression and activity, or as a target of gene therapy.

Claim 1; SEQ ID NO 4183; 305pp; English.

The invention relates to a novel human polynucleotide and the encoded polypeptide. A polynucleotide of the invention ADM05202-ADM06773 is useful as a primer for synthesizing the polynucleotide or as a probe for detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are useful in gene therapy, for developing a diagnostic marker or medicines for regulating their expression and activity, or as a target of gene therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides are useful as pharmaceutical agents. The present sequence represents a protein sequence of the invention.

Sequence 244 AA;

Query Match 99.6%; Score 1281; DB 7; Length 244;
Best Local Similarity 99.6%; Pred. No. 3.4e-112;
Matches 243; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

1 MEMCILLIWAQGLRQAPLASGMGTGTTTETGNISAEKGSIILOCHSSTTAQVYVNB 60
1 MEMCILLIWAQGLRQAPLASGMGTGTTTETGNISAEKGSIILOCHSSTTAQVYVNB 60
61 OODOLLAICNADLGNIHSPSPFDVAPRGGLTLOSLTVNDTGEYFCIYHTYPPDQTYG 120
61 OODOLLAICNADLGNIHSPSPFDVAPRGGLTLOSLTVNDTGEYFCIYHTYPPDQTYG 120
61 OODOLLAICNADLGNIHSPSPFDVAPRGGLTLOSLTVNDTGEYFCIYHTYPPDQTYG 120
121 RIFLEVLSSVAHGARGQIPILGMAATLVITCTAVIVVVALTRKKALRIHSVGDRL 180
121 RIFLEVLSSVAHGARGQIPILGMAATLVITCTAVIVVVALTRKKALRIHSVGDRL 180
181 RKSAGQEWSPSPSPSCVQABAPAGLCGROGDECAIHDYFNTLSYSLGNCSPF 240
181 RKSAGQEWSPSPSPSPSCVQABAPAGLCGROGDECAIHDYFNTLSYSLGNCSPF 240

```